Chairman of MCM Capital and Non-Executive Director of Vulcan Two Group PLC. Founder and CEO of several UK public listed companies including MDY Healthcare PLC and TripleArc PLC. Trained at Guy's Hospital Medical School.

Director of MCM Capital. Former CEO of financial services software business RightIndem. Previously European Strategy Director for global insurance services outsourcer, Innovation Group PLC and Insurance MD of Opun acquired by John Lewis.

Professor, Research and Development Lead for the Department of Diabetes & Endocrinology, Nutrition & Obesity at Guy’s and St Thomas’ NHS Foundation Trust. Member of European Society for Endocrinology Policy Unit.

Eight years’ capital markets experience. Previously Head of Healthcare Equity Research at Goodbody. ICAEW Chartered Accountant and PhD in Epidemiology of Metabolic Health.

Professor, Research and Development Lead for the Department of Diabetes & Endocrinology, Nutrition & Obesity at Guy’s and St Thomas’ NHS Foundation Trust. Member of European Society for Endocrinology Policy Unit.

Leading consultant and specialist in diabetes and endocrinology at The Royal Free NHS Trust. Associate Professor at UCL. A principal investigator in cardiovascular outcomes trials for Novo Nordisk and advisory roles for Eli Lilly and AstraZeneca.

Professor of Internal Medicine in the Department of Systems Medicine of the University of Rome, Chief of the Internal Medicine Unit and Obesity Center (EASO accredited Collaborating Centre for Obesity Management) at the University Hospital Policlinico Tor Vergata, Director of the Specialization School in Internal Medicine, and Treasurer and member of the Board of Trustees of the European Association for the Study of Obesity (EASO).

Dr. Zanariah Hussein is a Consultant Physician and Endocrinologist serving as the Head of Endocrinology for the Malaysian Ministry of Health and Hospital Putrajaya. She chairs the national endocrine fellowship program and has co-authored multiple clinical guidelines for diabetes and metabolic disorders. A Past President of the Malaysian Endocrine and Metabolic Society (MEMS), her research focuses on diabetes technology, adrenal tumors, and neuroendocrine health.

NIHR Advanced Fellow and Research Fellow/Lecturer in Nutrition and Dietetics course at UCL. PhD in Medicine from Imperial College London. Chair of the Specialist Obesity Group for the British Dietetic Association. Board of Trustees for the Academy of Nutrition Science.

Behaviour change and health psychology specialist at University College London. Behaviour science and Improvement Lead for Intensive Care Unit at UCL Hospital NHS Foundation Trust. Cognitive behaviour practitioner for people living with obesity.

Consultant Nephrologist and General Physician at Darent Valley Hospital, Kent and an Honorary Consultant at King's College Hospital. Previously Divisional Medical Director at Dartford & Gravesham NHS Trust. Awarded MBE in the Queen's Honour List for Services to the NHS in 2020.

Professor Sir Jonathan brings extensive experience in public health, government, academia, and the pharmaceutical industry. As Deputy Chief Medical Officer to HM Government from 2017 to 2022, he played a key role in shaping the UK's response to the COVID-19 pandemic. He has led major global health initiatives in partnership with the World Health Organisation and the former Public Health England. Sir Jonathan has held senior leadership positions at SmithKline Beecham (now part of GSK), Roche, and Aventis Pasteur MSD (now part of Sanofi).

Pinder recently served as General Manager and Corporate Vice President at Novo Nordisk UK, leading the Company through the development and commercialisation of GLP-1s in the UK market. He brings a track record in strategic health innovation, digital transformation, and executive leadership, with over 20 years of senior commercial and leadership life sciences experience, having held a variety of senior roles including GSK, AstraZeneca and Smith & Nephew. He also served as President of the Association of the British Pharmaceutical Industry (ABPI), Chairman of the Confederation of Business Industry’s (CBI) Health Council, and Vice Chair of the European Medicines Group.

Experienced CEO having led Oxford Biomedica for 14 years and into the FTSE 250. Lead deal and execution of AstraZeneca COVID-19 vaccine manufacturing for the UK for which he was awarded a CBE in 2021. Held senior roles at Cephalon and Serono. Previously non-executive director of Ergomed, providing specialised services to the pharmaceutical industry.

Director of MCM Capital. Former CEO of financial services software business RightIndem. Previously European Strategy Director for global insurance services outsourcer, Innovation Group PLC and Insurance MD of Opun acquired by John Lewis.

Professor, Research and Development Lead for the Department of Diabetes & Endocrinology, Nutrition & Obesity at Guy’s and St Thomas’ NHS Foundation Trust. Member of European Society for Endocrinology Policy Unit.

Eight years’ capital markets experience. Previously Head of Healthcare Equity Research at Goodbody. ICAEW Chartered Accountant and PhD in Epidemiology of Metabolic Health.

Laura's clinical leadership bridges healthcare and digital innovation to deliver real-world patient impact. She holds an MBBS and a BSc in Advanced Anatomy and Human Biology from King’s College London, and has served as a CQC Registered Manager and Clinical Safety Sponsor supporting DTAC compliance.

Rochelle brings over 20 years of leadership experience in healthcare, spanning clinical innovation, digital transformation, and strategic product development. She has worked across the NHS and global healthtech organisations, led high-impact product portfolios to deliver measurable outcomes for patients, clinicians and health systems. Before joining Reset Health Rochelle was Chief Product Officer for Optum.

Ling was previously a management consultant focused on delivering complex transformation programmes in the healthcare and life sciences industries. Prior to Reset Health, Ling was the third employee in a now 200+ strong team healthcare scale up, leading and managing multiple key strategic initiatives since its inception. She holds a Masters in Biochemistry from University of Oxford and has completed a Wellcome Trust funded PhD in Cancer Therapeutics.

Andrew has 25 years' experience in software engineering. Working mostly in consultancies, he has experience in many different sectors delivering business critical solutions to large corporations like BT, Renault, BUPA, LIDL, NS&I, Biogen, Black Horse, Volkswagen and more. In the last ten years he has been leading at the CTO level, building teams, establishing governance, distilling requirements, architecting solutions whilst still remaining in touch with the cutting edge of technology. Andrew has a Masters in Engineering and an MBA.

With over 25 years' experience, Alex brings his experience in building and scaling tech products across healthcare, biotech, SaaS, and machine learning. He has a proven track record of turning complex ideas into products that make a real-world impact. He has helped two technology businesses achieve successful exits, first to GE Healthcare and more recently to AXA Health.

Luca was previously the Managing Director of Eli Lilly India as well as General Manager for Eli Lilly Romania. During his tenure, he successfully strengthened Eli Lilly's presence in these regions, spearheading initiatives that enhanced patient access to innovative treatments and addressed unmet medical needs.

David is a neuroscientist and technologist, holds a PhD in AI and Human Behaviour and an MSc in Psychology Research Methods. His previous roles include Chief Product and Science Officer at Healios, Head of Research at Huma Therapeutics, and Founder CEO/CPO of BioBeats, a neuroscience and biometrics start up which he successfully exited to Huma. He leads our advanced AI strategy and oversees regulatory compliance with MHRA, FDA, and EU MDR, while directing robust clinical validation studies.

Davide is a researcher and entrepreneur specialising in AI and physiological signals. Previously, he founded BioBeats, serving as CTO through its acquisition by Huma, before becoming Head of AI. We was also CTO at Healios Ltd, where he deployed GenAI solutions for clinical and administrative tasks. A dual-doctorate scholar, Davide holds a PhD from the University of Pisa and a DPhil from Oxford, where he remains a Research Associate specialising in Bayesian HRV estimation.

Professor, Research and Development Lead for the Department of Diabetes & Endocrinology, Nutrition & Obesity at Guy’s and St Thomas’ NHS Foundation Trust. Member of European Society for Endocrinology Policy Unit.

Leading consultant and specialist in diabetes and endocrinology at The Royal Free NHS Trust. Associate Professor at UCL. A principal investigator in cardiovascular outcomes trials for Novo Nordisk and advisory roles for Eli Lilly and AstraZeneca.

Laura's clinical leadership bridges healthcare and digital innovation to deliver real-world patient impact. She holds an MBBS and a BSc in Advanced Anatomy and Human Biology from King’s College London, and has served as a CQC Registered Manager and Clinical Safety Sponsor supporting DTAC compliance.

NIHR Advanced Fellow and Research Fellow/Lecturer in Nutrition and Dietetics course at UCL. PhD in Medicine from Imperial College London. Chair of the Specialist Obesity Group for the British Dietetic Association. Board of Trustees for the Academy of Nutrition Science.

Behaviour change and health psychology specialist at University College London. Behaviour science and Improvement Lead for Intensive Care Unit at UCL Hospital NHS Foundation Trust. Cognitive behaviour practitioner for people living with obesity.

Consultant Nephrologist and General Physician at Darent Valley Hospital, Kent and an Honorary Consultant at King's College Hospital. Previously Divisional Medical Director at Dartford & Gravesham NHS Trust. Awarded MBE in the Queen's Honour List for Services to the NHS in 2020.

Dr Claudia Ashton brings a multidisciplinary background spanning psychology, neurosurgery and general practice. She leads the clinical MDT in specialist weight management and works across the business to deliver new pathways and services, ensuring safe, evidence-based care at scale.

Dr. Tom Curtis combines 15 years of NHS general practice experience with over five years in digital obesity care. His background includes senior system leadership as Primary Care Medical Director and Non-Executive Director for the Suffolk GP Federation, representing 57 practices.

Dr. Catherine Hyatt is a practising GP with over 10 years’ clinical experience. She specialises in creating accurate, accessible and engaging medical content, bringing over five years’ experience in developing evidence-based resources that help patients understand their treatment and make informed decisions about their health.